Amicus Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Amicus Therapeutics

26/02/2024 14:59

* Amicus Therapeutics Inc  FOLD.OQ   FOLD.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
28 for the period ending December 31 2023
    * The Philadelphia Pennsylvania-based  company is expected
to
report a 29.8% increase in revenue to $114.335 million from
$88.1 million a year ago, according to the mean estimate from 10
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Amicus Therapeutics Inc
is for
a loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $20.00​, above​ its last closing price
of $13.53. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.08       -0.08      -0.07     Beat    7.4
 Jun. 30 2023  -0.12       -0.12      -0.15     Missed  -21.6
 Mar. 31 2023  -0.16       -0.15      -0.18     Missed  -22.7​
 Dec. 31 2022  -0.13       -0.13      -0.19     Missed  -50.4
 ​​Sep.        -0.19       -0.19      -0.12     Beat    35.6
 30 2022                                                
 Jun. 30 2022  -0.22       -0.22      -0.21     Beat    3.2​
 Mar. 31 2022  -0.26       -0.25      -0.30     Missed  -17.6
 Dec. 31 2021  -0.15       -0.16      -0.29     Missed  -85.9
 This summary was machine generated February 26 at 14:59 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)